1. Home
  2. AADI vs RNLX Comparison

AADI vs RNLX Comparison

Compare AADI & RNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AADI
  • RNLX
  • Stock Information
  • Founded
  • AADI 2011
  • RNLX 2018
  • Country
  • AADI United States
  • RNLX United States
  • Employees
  • AADI N/A
  • RNLX N/A
  • Industry
  • AADI Biotechnology: Pharmaceutical Preparations
  • RNLX Medical Specialities
  • Sector
  • AADI Health Care
  • RNLX Health Care
  • Exchange
  • AADI Nasdaq
  • RNLX Nasdaq
  • Market Cap
  • AADI 33.6M
  • RNLX 32.8M
  • IPO Year
  • AADI N/A
  • RNLX 2020
  • Fundamental
  • Price
  • AADI $1.57
  • RNLX $0.31
  • Analyst Decision
  • AADI Buy
  • RNLX
  • Analyst Count
  • AADI 2
  • RNLX 0
  • Target Price
  • AADI $5.00
  • RNLX N/A
  • AVG Volume (30 Days)
  • AADI 294.5K
  • RNLX 5.1M
  • Earning Date
  • AADI 08-07-2024
  • RNLX 05-15-2024
  • Dividend Yield
  • AADI N/A
  • RNLX N/A
  • EPS Growth
  • AADI N/A
  • RNLX N/A
  • EPS
  • AADI N/A
  • RNLX N/A
  • Revenue
  • AADI $23,840,000.00
  • RNLX $2,221,000.00
  • Revenue This Year
  • AADI $4.21
  • RNLX $48.40
  • Revenue Next Year
  • AADI $8.61
  • RNLX $104.00
  • P/E Ratio
  • AADI N/A
  • RNLX N/A
  • Revenue Growth
  • AADI 26.97
  • RNLX N/A
  • 52 Week Low
  • AADI $1.28
  • RNLX $0.22
  • 52 Week High
  • AADI $7.24
  • RNLX $3.33
  • Technical
  • Relative Strength Index (RSI)
  • AADI 50.71
  • RNLX 42.93
  • Support Level
  • AADI $1.46
  • RNLX $0.28
  • Resistance Level
  • AADI $1.69
  • RNLX $0.35
  • Average True Range (ATR)
  • AADI 0.10
  • RNLX 0.04
  • MACD
  • AADI 0.02
  • RNLX 0.01
  • Stochastic Oscillator
  • AADI 67.75
  • RNLX 28.33

About AADI Aadi Bioscience Inc.

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

About RNLX Renalytix plc

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Share on Social Networks: